Previous 10 | Next 10 |
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Alpine Immune Sciences Inc. (ALPN) is expected to report $-0.35 for Q3 2023
2023-11-10 10:34:03 ET More on Vera Therapeutics Vera Therapeutics' Promising Atacicept Drug Targets IgAN Guggenheim starts Vera at buy, sees IgAN drug as "well positioned" Seeking Alpha’s Quant Rating on Vera Therapeutics Historical earnings data for ...
2023-11-07 08:36:07 ET Losers: Ventyx Biosciences ( VTYX ) -76% announces results from the phase 2 trial of VTX958 in patients with moderate to severe plaque Psoriasis and provides corporate update. Alto Ingredients ( ALTO ) -50% reports third quarter 2023 re...
2023-11-07 03:50:12 ET More on Alpine Immune Sciences Alpine Immune Sciences: November 2023 Data Release Could Get Ball Rolling Alpine Immune Sciences: Going Strong But For How Long? Alpine Immune gains on early clinical data for kidney disease therapy Alpine...
Alpine Immune Sciences, Inc. (Nasdaq: ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the pricing of its underwritten public offering of 8,800,000 shares of its common stock and, in lieu of shares ...
2023-11-06 06:29:55 ET More on Alpine Immune Sciences Alpine Immune Sciences: November 2023 Data Release Could Get Ball Rolling Alpine Immune Sciences: Going Strong But For How Long? Alpine Immune gains on early clinical data for kidney disease therapy Alpine...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, announced the Company presented new preclinical data on povetacicept in myasthenia gravis at the American Association...
2023-11-02 14:45:07 ET More on Alpine Immune Alpine Immune Sciences: November 2023 Data Release Could Get Ball Rolling Alpine Immune Sciences: Going Strong But For How Long? Alpine Immune Sciences appoints Wolfgang Dummer as CMO Seeking Alpha’s Quant R...
2023-11-02 13:15:49 ET More on etc. Dynatrace, Inc. (DT) Q2 2024 Earnings Call Transcript Geron Corporation 2023 Q3 - Results - Earnings Call Presentation Gates Industrial: Encouraging Q3 Report Needed To Finally Create A Floor For The Stock Icahn Enterprises...
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...
2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...